# Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

> **NCT07665684** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 67 (estimated)

## Conditions studied

- Pancreas Ductal Adenocarcinoma
- Pancreas Cancer, Metastatic
- Pancreatic Adenocarcinoma Metastatic
- Adenosquamous Carcinoma of the Pancreas
- Mucinous Adenocarcinoma

## Interventions

- **DRUG:** Samuraciclib + Gemcitabine & Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT07665684
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-05
- **Final completion:** 2030-05
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665684, "Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*